2.625
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché AYTU Giù?
Forum
Previsione
Frazionamento azionario
Aytu Biopharma Inc Borsa (AYTU) Ultime notizie
What analysts say about Aytu BioPharma Inc. stockDynamic profit opportunities - PrintWeekIndia
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition - MSN
What risks could impact Aytu BioPharma Inc. stock performanceHigh-velocity capital appreciation - jammulinksnews.com
What drives Aytu BioPharma Inc. stock priceExplosive trading growth - Autocar Professional
Aytu BioPharma Inc. Stock Analysis and ForecastPhenomenal trading returns - PrintWeekIndia
What analysts say about Aytu BioPharma Inc. stock outlookJaw-dropping returns - jammulinksnews.com
Is Aytu BioPharma Inc. a good long term investmentConsistent high-performance stocks - jammulinksnews.com
11 Best High Return Penny Stocks to Buy Now - Insider Monkey
What makes Aytu BioPharma Inc. stock price move sharplyWeekly Big Movers - beatles.ru
Why Aytu BioPharma Inc. stock attracts strong analyst attentionDouble Profit With Half Risk - beatles.ru
How Aytu BioPharma Inc. stock performs during market volatilityTrending Stock Alert - Newser
Aytu BioPharma Completes $15 Million Debt Refinancing - ACCESS Newswire
Aytu BioPharma (NASDAQ:AYTU) Downgraded by Wall Street Zen to Buy - Defense World
Aytu Boosts Liquidity with Eclipse Loan Extension - MSN
Aytu BioPharma (NASDAQ:AYTU) Now Covered by Lake Street Capital - Defense World
Aytu BioPharma (AYTU): Lake Street Initiates Coverage with Buy Rating | AYTU Stock News - GuruFocus
Lake Street Initiates Aytu BioPharma at Buy With $8 Price Target - MarketScreener
Aytu BioPharma (NASDAQ:AYTU) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
AYTU: Ascendiant Capital Initiates Coverage with 'Buy' Rating | AYTU Stock News - GuruFocus
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome - ACCESS Newswire
AYTU SEC FilingsAytu Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aytu BioPharma (NASDAQ:AYTU) Upgraded by Wall Street Zen to Strong-Buy Rating - Defense World
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) - ACCESS Newswire
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) - ACCESS Newswire
Aytu BioPharma Lands $13M Financing Deal to Launch Revolutionary Depression Drug in $22B Market - Stock Titan
Aytu BioScience Expands Lending Agreement for EXXUA Launch - TipRanks
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):